Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07660939 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 6 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Interventions: GPRC5D-Targeted PET/CT Imaging (Diagnostic Test) to GPRC5D-Targeted PET/CT Imaging (Diagnostic Test)
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
    • Publications: details revised at 2 of 2 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma. Participants will undergo GPRC5D-targeted PET/CT, 18F-FDG PET/CT, and 68Ga-BCMA PET/CT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment. The study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET/CT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.
Trial Details
NCT Number NCT07660939
Lead Sponsor Peking University First Hospital
Conditions
(from sponsor)		 Plasma Cell Disorders, Multiple Myeloma (MM)
Related terms Multiple Myeloma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov